MedTrace Logo

Proof of Concept of Hybrid Robotics for Gait Rehabilitation of Persons Post-stroke

NCT06436898 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-05-31

No results posted yet for this study

Summary

Persons post-stroke suffer from hemiparesis affecting the functional abilities of the controlesional lower limb. Improving walking is therefore a primary rehabilitation goal for such patients. Robotic-Assisted Rehabilitation (RAR, e.g. exoskeletons) and Functional Electrical Stimulation (FES) are promising techniques to facilitate the functional recovery after stroke. allowing benefits to be maintained over long term.

Conditions

  • Stroke Sequelae
  • Gait, Hemiplegic

Interventions

DEVICE

Combined overground gait exoskeleton and FES applied to lower limb

Gait rehabilitation for persons with stroke, with an overground exoskeleton combined with an electromyographically controlled FES applied to lower limb muscles during gait.

DEVICE

Overground gait exoskeleton

Gait rehabilitation for persons with stroke, with an overground exoskeleton.

Sponsors & Collaborators

  • Istituto Italiano di Tecnologia

    collaborator OTHER

  • Istituto Nazionale di Ricovero e Cura per Anziani

    collaborator OTHER

  • Fondazione Don Carlo Gnocchi Onlus

    lead OTHER

Principal Investigators

  • Maurizio Ferrarin, PhD · Research Head of Biomedical Technology Department

  • Andrea Corsonello, PhD · Research Head of the Neurological Unit

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-07-01
Completion
2025-11-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06436898 on ClinicalTrials.gov